Commercial and Pipeline Insight: Opioids - Short acting and anti-abuse technologies set to fragment

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2008-03-26

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value.


Scope

  • Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.
  • Analysis of patient potential, unmet needs and clinical trial design in the opioid market.
  • Overview of key marketed brands, late- and early-stage pipeline drugs.
  • Identification of future market events that are expected to affect opioid revenues.


    • Report Highlights
    Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalon's Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.

    The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.

    The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnson's market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.


    Reasons to Purchase

  • Benchmark key late-stage pipeline opioids against current market leading brands.
  • Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
  • Understand unmet needs and opportunities in the opioid market based on key opinion leader comments.

    • Table of Contents

    Other users found this report page using the following search terms: pain Opioids opiate OxyContin duragesic fentanyl patch fentora actiq kadian avinza opana instanyl opioids abuse acting fentanyl 2008 sales market anti short

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.